Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating Activities
Net (loss) income	$ (137,942)	$ 37,219
Adjustments to reconcile net (loss) income to cash from operating activities:
Depreciation and amortization	41,294	45,500
Credit loss expense	15,582	1,957
Write-downs	13,339	1,027
Deferred income tax expense	23,142	1,035
Share-based and other non-cash compensation	16,345	17,397
Unrealized foreign currency exchange (gain) loss	(394)	214
Loss in fair value of investments	939	2,543
Equity in losses of investees	1,858	56
Changes in assets and liabilities:
Accounts receivable	30,350	9,613
Inventories	(10,278)	(13,422)
Film assets	(6,177)	(15,405)
Deferred revenue	5,233	(2,599)
Changes in other operating assets and liabilities	(24,109)	(17,878)
Net cash (used in) provided by operating activities	(30,818)	67,257
Investing Activities
Purchase of property, plant and equipment	(658)	(5,528)
Investment in equipment for joint revenue sharing arrangements	(5,289)	(31,099)
Acquisition of other intangible assets	(1,661)	(1,874)
Investment in equity securities		(15,153)
Net cash used in investing activities	(7,608)	(53,654)
Financing Activities
Increase in revolving credit facility borrowings	280,244	35,000
Repayment of revolving credit facility borrowings		(55,000)
Credit facility amendment fees paid	(1,026)
Settlement of restricted share units and options	(2,815)	(8,589)
Treasury stock repurchased for future settlement of restricted share units	(271)	(1,572)
Repurchase of common shares, IMAX China	(36,624)	(2,659)
Taxes withheld and paid on employee stock awards vested	(251)	(508)
Common shares issued - stock options exercised		2,391
Issuance of subsidiary shares to non-controlling interests (net of return on capital)		1,106
Dividends paid to non-controlling interests	(4,214)	(4,384)
Net cash provided by (used in) financing activities	233,509	(53,372)
Effects of exchange rate changes on cash	630	727
Increase (decrease) in cash and cash equivalents during period	195,713	(39,042)
Cash and cash equivalents, beginning of period	109,484	141,590
Cash and cash equivalents, end of period	305,197	102,548
IMAX China
Financing Activities
Repurchase of common shares, IMAX China	$ (1,534)	$ (19,157)